Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in two upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 12:50 PM ET in New York. Additionally, MindMed will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 17, 2025, at 7:00 AM ET. Audio webcasts and replays will be available on MindMed's Investor Relations website for 90 days after each event.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for three new non-executive employees. The grants consist of options to purchase 53,350 common shares with grant dates of May 5 and May 19, 2025. The options' exercise price equals the closing price of MindMed's shares on the last trading day before each grant.
The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years, contingent on continued employment. These grants were approved by MindMed's Compensation Committee on May 2, 2024, in compliance with NASDAQ Rule 5635(c)(4) and were issued outside the company's equity incentive plans.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management team will engage in a fireside chat and one-on-one meetings on May 21, 2025, at 2:05 PM ET in New York. The presentation will be available via webcast, with replays accessible on MindMed's Investor Relations website for up to 90 days after the event.
MindMed (MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has scheduled its Q1 2025 financial results announcement and business updates for May 8, 2025, at 8:00 a.m. ET. The company will host a live webcast with a Q&A session for analysts. Participants are advised to join 15 minutes before the start time. The webcast replay will be available through the company's Investor Relations website for at least 30 days after the event.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for three new non-executive employees. The grants consist of options to purchase 121,500 common shares with an effective date of April 21, 2025.
The options' exercise price will match the closing price of MindMed's common shares on April 18, 2025. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years, contingent on continued employment. These grants were approved by MindMed's Compensation Committee on April 16, 2025, in compliance with NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD) has initiated its Phase 3 Emerge study by dosing the first patient with MM120 ODT, a proprietary form of LSD, for Major Depressive Disorder (MDD) treatment. The study will evaluate MM120 ODT 100 µg versus placebo, enrolling approximately 140 U.S. participants.
The 52-week Emerge study consists of two parts: a 12-week double-blind, placebo-controlled phase and a 40-week extension period. The primary endpoint will measure changes in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6. Topline data from the double-blind period is expected in H2 2026.
This marks MindMed's third Phase 3 study of MM120 ODT, alongside ongoing Voyage and Panorama studies in Generalized Anxiety Disorder (GAD). The development builds on positive Phase 2b results, which showed significant MADRS score improvements after a single MM120 100 µg dose compared to placebo.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for four new non-executive employees. The grants consist of options to purchase 88,950 common shares with an effective date of March 24, 2025.
The options' exercise price will match the closing price of MindMed's common shares on March 21, 2025. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the subsequent three years, contingent on continued employment. These grants, approved by MindMed's Compensation Committee on March 19, 2025, were issued outside the company's equity incentive plans as employment inducements under NASDAQ Rule 5635(c)(4).
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
